Trimetrexate combined with cisplatin or etoposide in the treatment of nonsmall cell lung cancer: A pilot study

Academic Article


  • Trimetrexate glucuronate in combination therapy with cisplatin or etoposide was evaluated in non-small cell lung cancer patients in a pilot, dose escalation study. Trimetrexate was administered intravenously together with 20 mg/m2 cisplatin or 50 mg/ m2 etoposide for 5 consecutive days at an initial dose of 4 mg/m2. Courses were repeated at 3 week intervals with the trimetrexate dosage escalated according to patient tolerance. In the 12 patients treated to date, reversible myelosuppression, consisting of leukopenia and thrombocytopenia, and nonhematologic grade 1 and 2 toxicities were observed. The study is ongoing. The maximum tolerated trimetrexate dosage levels in combination therapy will be established. © 1988.
  • Author List

  • Maroun JA; Natale RB; Robert F
  • Start Page

  • 38
  • End Page

  • 40
  • Volume

  • 15
  • Issue

  • 2 SUPPL. 2